dara biosciences inc (DARA) Key Developments
DARA BioSciences, Inc. Signs Medicare Part D Prescription Drug Program Reimbursement Agreement with Comprehensive Health Management, Inc
Mar 5 14
DARA BioSciences, Inc. announced that the company signed a Medicare Part D Prescription Drug Program Reimbursement Agreement with Comprehensive Health Management, Inc. (CHMI) providing formulary status for the WellCare(R) Group of Companies for Soltamox(R) (tamoxifen citrate) oral solution, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer. Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen. DARA holds exclusive U.S. marketing rights to Soltamox, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer. Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen.
DARA BioSciences Regains Compliance With NASDAQ Bid Price Requirement
Feb 25 14
DARA BioSciences, Inc. announced that it has received notice from the NASDAQ Listing Qualifications Staff that it has regained compliance with the minimum $1.00 bid price per share requirement. The previously disclosed NASDAQ delisting matter related to the Company's bid price compliance is now closed.
DARA BioSciences, Inc Presents at 26th Annual ROTH Conference, Mar-12-2014 10:00 AM
Feb 20 14
DARA BioSciences, Inc Presents at 26th Annual ROTH Conference, Mar-12-2014 10:00 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: David J. Drutz, Chief Executive Officer, Chief Medical Officer and Director.
DARA BioSciences, Inc Files with the Secretary of State of the State of Delaware Certificate of Amendment of Restated Certificate of Incorporation
Feb 6 14
DARA BioSciences Inc. filed with the Secretary of State of the State of Delaware a certificate of amendment of the company's restated certificate of incorporation to implement the reverse stock split effective as of February 10, 2014.
DARA BioSciences, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013
Feb 4 14
DARA BioSciences Inc. announced earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net product revenues of $182,300 against $53,600 million a year ago. Net loss attributed to controlling interest was $2,354,100 against $1,871,300 a year ago.
For the year, the company reported a net loss attributable to controlling interest of $9,965,014 or $0.39 per share as compared to a net loss attributable to controlling interest of $7,311,033 or $0.60 per share for the year ended December 31, 2012. The increase in loss was primarily a result of the costs incurred in the establishment of a sales and marketing infrastructure to support the promotion of the company's oncology and oncology supportive care products as well as a related increase in general and administrative expenses as the company continued its transition from what had been solely a research and development company. Net product revenues were $419,300 against $53,600 a year ago.